PRMT5 and astrocytoma (excluding glioblastoma): In our current study, we have observed that there were significant differences in PFS of all G4 astrocytoma with upregulated PRMT5, receiving TMZ or TMZ plus other chemotherapeutic agents, regardless of IDH or MGMT-promoter status (Fig. 3).